New hope for rare amyloidosis patients with targeted drug combo
NCT ID NCT07335887
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests a new drug, Sonrotoclax, combined with steroids and possibly another drug (daratumumab) in 39 adults with a rare disease called AL amyloidosis who have a specific genetic marker (t(11;14)). The goal is to see if this treatment can reduce harmful protein buildup and improve organ function. Participants will receive treatment for 12 cycles, and researchers will monitor blood responses and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS (AL) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.